NCT03925376 is a clinical trial of Redo cardiac surgery in Redo Cardiac Surgery, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT03925376?

NCT03925376 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT03925376?

Interventions in NCT03925376: Redo cardiac surgery.

What condition does NCT03925376 study?

NCT03925376 studies Redo Cardiac Surgery.

Is NCT03925376 still recruiting?

NCT03925376 is currently status unknown. Last updated 24 April 2019.

Last reviewed 2019-04-24 · How we verify

NCT03925376

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Factors of Patients Undergoing Redo Cardiac Surgery

Status unknown Last updated 24 April 2019

What this trial tests

trial testing Redo cardiac surgery in Redo Cardiac Surgery in 1,200 participants. Status unknown.

Timeline

21 April 2019

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,200
Start date	21 April 2019
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Redo cardiac surgery

Conditions studied

Redo Cardiac Surgery — all drugs for Redo Cardiac Surgery →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 90, any sex, with Redo Cardiac Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the prognostic significance of baseline characteristics for patients undergoing redo cardiac surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03925376 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 24 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03925376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing